These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37327540)

  • 1. Trends in the use of neoadjuvant chemotherapy for low-grade serous ovarian cancer in the United States.
    Silberman JN; Bercow AS; Gockley AA; Eisenhauer EL; Sisodia R; Randall T; Del Carmen MG; Goodman A; Castro CM; Melamed A; Bregar AJ
    Gynecol Oncol; 2023 Aug; 175():60-65. PubMed ID: 37327540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
    Matsuo K; Matsuzaki S; Maeda M; Rau AR; Yoshihara K; Tamura R; Shimada M; Machida H; Mikami M; Klar M; Roman LD; Wright JD; Sood AK; Gershenson DM
    JAMA Netw Open; 2023 Jun; 6(6):e2318602. PubMed ID: 37326992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of HE4 in advanced-stage, high-grade serous ovarian cancer: Analysis of HE4 kinetics during NACT, predicting surgical outcome and recurrence in comparison to CA125.
    AlSomairi A; Himayda S; Altelmesani A; Lee YJ; Lee JY
    Gynecol Oncol; 2024 Feb; 181():155-161. PubMed ID: 38176127
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Possible candidate population for neoadjuvant chemotherapy in women with advanced ovarian cancer.
    Matsuo K; Matsuzaki S; Nusbaum DJ; Maoz A; Oda K; Klar M; Roman LD; Sood AK
    Gynecol Oncol; 2021 Jan; 160(1):32-39. PubMed ID: 33196436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upfront debulking surgery versus interval debulking surgery for advanced tubo-ovarian high-grade serous carcinoma and diffuse peritoneal metastases treated with peritonectomy procedures plus HIPEC.
    Biacchi D; Accarpio F; Ansaloni L; Macrì A; Ciardi A; Federici O; Spagnoli A; Cavaliere D; Vaira M; Sapienza P; Sammartino P
    J Surg Oncol; 2019 Dec; 120(7):1208-1219. PubMed ID: 31531879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar Overall Survival Using Neoadjuvant Chemotherapy or Primary Debulking Surgery in Patients Aged Over 75 Years with High-Grade Ovarian Cancer.
    Piedimonte S; Kessous R; Laskov I; Abitbol J; Kogan L; Yasmeen A; Salvador S; Lau S; Gotlieb WH
    J Obstet Gynaecol Can; 2020 Nov; 42(11):1339-1345. PubMed ID: 32859533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy versus surgery for initial treatment in advanced ovarian epithelial cancer.
    Coleridge SL; Bryant A; Lyons TJ; Goodall RJ; Kehoe S; Morrison J
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684686
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors associated with delivery of neoadjuvant chemotherapy in women with advanced stage ovarian cancer.
    Hinchcliff E; Melamed A; Bregar A; Diver E; Clemmer J; Del Carmen M; Schorge JO; Alejandro Rauh-Hain J
    Gynecol Oncol; 2018 Jan; 148(1):168-173. PubMed ID: 29128105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of upfront surgery versus neoadjuvant chemotherapy followed by interval debulking surgery for patients with stage IIIC and IV ovarian cancer, SGOG SUNNY (SOC-2) trial concept.
    Jiang R; Zhu J; Kim JW; Liu J; Kato K; Kim HS; Zhang Y; Zhang P; Zhu T; Aoki D; Yu A; Chen X; Wang X; Zhu D; Zhang W; Jia H; Shi T; Gao W; Yin S; Feng Y; Xiang L; Okamoto A; Zang R
    J Gynecol Oncol; 2020 Sep; 31(5):e86. PubMed ID: 32808504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary cytoreductive surgery compared with neoadjuvant chemotherapy in patients with
    Kim SR; Parbhakar A; Li X; Bernardini MQ; Hogen L; May T
    Int J Gynecol Cancer; 2024 Jun; 34(6):879-885. PubMed ID: 38548312
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic Concerns regarding Laparoscopic Cytoreductive Surgery in Patients with Advanced Ovarian Cancer Submitted to Neoadjuvant Chemotherapy.
    Favero G; Macerox N; Pfiffer T; Köhler C; da Costa Miranda V; Estevez Diz Mdel P; Fukushima JT; Baracat EC; Carvalho JP
    Oncology; 2015; 89(3):159-66. PubMed ID: 25968072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Optimizing the treatment of ovarian cancer: Neoadjuvant chemotherapy and interval debulking versus primary debulking surgery for epithelial ovarian cancers likely to have suboptimal resection.
    Gill SE; McGree ME; Weaver AL; Cliby WA; Langstraat CL
    Gynecol Oncol; 2017 Feb; 144(2):266-273. PubMed ID: 27916269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer.
    Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R
    Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors Predicting Use of Neoadjuvant Chemotherapy Compared With Primary Debulking Surgery in Advanced Stage Ovarian Cancer-A National Cancer Database Study.
    Leiserowitz GS; Lin JF; Tergas AI; Cliby WA; Bristow RE
    Int J Gynecol Cancer; 2017 May; 27(4):675-683. PubMed ID: 28328580
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of neoadjuvant chemotherapy in the management of low-grade serous carcinoma of the ovary and peritoneum: Further evidence of relative chemoresistance.
    Cobb LP; Sun CC; Iyer R; Nick AM; Fleming ND; Westin SN; Sood AK; Wong KK; Silva EG; Gershenson DM
    Gynecol Oncol; 2020 Sep; 158(3):653-658. PubMed ID: 32709538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
    Piedimonte S; Murray C; Atenafu EG; Rouzbahman M; Lheureux S; May T
    Gynecol Oncol; 2024 Aug; 187():92-97. PubMed ID: 38735145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary debulking surgery versus primary neoadjuvant chemotherapy for high grade advanced stage ovarian cancer: comparison of survivals.
    Kobal B; Noventa M; Cvjeticanin B; Barbic M; Meglic L; Herzog M; Bordi G; Vitagliano A; Saccardi C; Skof E
    Radiol Oncol; 2018 Sep; 52(3):307-319. PubMed ID: 30210049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
    Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
    Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival and Surgical Approach among Women with Advanced Ovarian Cancer Treated with Neoadjuvant Chemotherapy.
    Persenaire C; Pyrzak A; Barber EL
    J Minim Invasive Gynecol; 2022 Mar; 29(3):375-384. PubMed ID: 34648931
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
    Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
    Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.